Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
about
Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizationsIntegrative study of physiological changes associated with bacterial infection in Pacific oyster larvaeRole of cytosolic phospholipase A2 in oxidative and inflammatory signaling pathways in different cell types in the central nervous systemDengue virus infection perturbs lipid homeostasis in infected mosquito cells.Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target.Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer.Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in ratsCytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.Aging-related Changes in Mouse Serum Glycerophospholipid ProfilesCytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.Targeting cytosolic phospholipase A2 α in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation.Cytosolic phospholipase A2α is critical for angiotensin II-induced hypertension and associated cardiovascular pathophysiology.Extra-hepatic metabolism of 7-ketocholesterol occurs by esterification to fatty acids via cPLA2α and SOAT1 followed by selective efflux to HDLMetabolomics reveals phospholipids as important nutrient sources during Salmonella growth in bile in vitro and in vivo.The RNA-binding protein HuR stabilizes cytosolic phospholipase A2α mRNA under interleukin-1β treatment in non-small cell lung cancer A549 CellsTuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.Novel Host Proteins and Signaling Pathways in Enteropathogenic E. coli Pathogenesis Identified by Global Phosphoproteome Analysis.A distal enhancer controls cytokine-dependent human cPLA2α gene expressionMembrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy.Attenuation of cysteamine-induced duodenal ulcer with Cochinchina momordica seed extract through inhibiting cytoplasmic phospholipase A2/5-lipoxygenase and activating γ-glutamylcysteine synthetase.Suppressive effects of PG201, an antiarthritic botanical formulation, on lipopolysaccharide-induced inflammatory mediators in Raw264.7 cells.Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies.In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.[Carboxyl-11 C]Labelling of Four High-Affinity cPLA2α Inhibitors and Their Evaluation as Radioligands in Mice by Positron Emission Tomography.Participation of Arachidonic Acid Metabolism in the Aortic Aneurysm Formation in Patients with Marfan Syndrome.
P2860
Q28286551-FAAD80FB-3044-426A-B432-5BB87D4B750DQ28488423-50F51287-36CD-4A27-A481-5CB270A54774Q34099708-74EF39E8-A3D1-4BF8-B670-1B3330C0F01BQ34211489-0D438796-6F16-413C-B5DD-69DC32854E87Q34320362-6414C5E8-1295-4B38-B971-B7308C6B2A61Q34472131-9CB92426-DF77-43B1-B6D6-4BD48F694A6CQ34476283-954D1D09-A6AA-49E0-B483-1009A7F5DD4BQ34785252-B04EB18F-3187-4E74-B9C8-A28223126654Q34800397-0F73AA4B-9608-4FDC-AB3B-5EE146061669Q34874275-049899B6-8982-4654-9D29-DC7A62F46670Q35067937-E21AE505-94AB-4085-A31B-090D322ECBF5Q35175554-41B07FB3-8CA8-47A4-8C1D-B7C065351EF0Q35187083-9EBAD167-87B4-4F35-BB33-05190112CBD2Q35192564-10121FD0-E3E4-4C6C-AC39-D618E8301D68Q35371734-8A46C741-A0F6-423F-8863-99753D112C96Q36049513-0375F62B-12EB-4465-B754-3AD8CCA545ACQ36103927-1FE031F1-0EBB-4628-A664-1F5BB81D0FB7Q36920601-9E543277-D969-4651-8CFC-5F8D9C28E5BBQ37031569-BCE07299-2A95-4826-83EF-57B00574FDF8Q37885347-DE7ED790-C73A-49E5-880F-5ABDEA63B86BQ39364183-3D602AA0-9BE9-4709-98CE-F3A266694900Q39374982-9639BB82-D8F7-4376-AF28-DBD4DD5094C8Q39487878-D6FCDD0A-215B-4979-A037-D2B16D9C3F4EQ42063640-7C1CAA88-2613-472A-B407-F52334ADD29CQ42454329-5DB35E5D-9E96-46F3-A4AA-01F833858182Q47565244-24B1B5B7-F920-457C-989F-DE0922C2E411Q50355330-800277A9-4875-4AEC-9F90-A0E047AE4229
P2860
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
@en
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
@nl
type
label
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
@en
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
@nl
prefLabel
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
@en
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
@nl
P2860
P1476
Cytosolic phospholipase A2 as a mediator of disease pathogenesis.
@en
P2093
Amanda Linkous
Eugenia Yazlovitskaya
P2860
P304
P356
10.1111/J.1462-5822.2010.01505.X
P577
2010-10-01T00:00:00Z